Want to see SCNI full AI Analyst Report?
Scinai Immunotherapeutics (SCNI) Ratios
Scinai Immunotherapeutics Ratios
SCNI's free cash flow for Q2 2026 was $-2.61M. For the 2026 fiscal year, SCNI's free cash flow was decreased by $-112.81K and operating cash flow was $-2.50M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.30 | 1.32 | 3.06 | 6.15 | 7.30 |
| Quick Ratio | 1.30 | 1.32 | 3.06 | 6.15 | 7.30 |
| Cash Ratio | 1.05 | 1.09 | 2.74 | 6.02 | 7.11 |
| Solvency Ratio | -1.95 | 1.86 | -0.27 | -0.18 | -0.25 |
| Operating Cash Flow Ratio | -3.81 | -3.51 | -5.27 | -3.11 | -3.04 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -23.69 | 0.00 | -29.90 |
| Net Current Asset Value | $ -1.47M | $ -1.08M | $ -16.59M | $ -14.46M | $ -13.21M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.19 | 0.16 | 1.18 | 0.80 | 0.91 |
| Debt-to-Equity Ratio | 0.28 | 0.21 | -4.50 | -12.24 | 29.77 |
| Debt-to-Capital Ratio | 0.22 | 0.17 | 1.29 | 1.09 | 0.97 |
| Long-Term Debt-to-Capital Ratio | 0.04 | 0.03 | 1.31 | 1.10 | 0.97 |
| Financial Leverage Ratio | 1.43 | 1.35 | -3.82 | -15.38 | 32.62 |
| Debt Service Coverage Ratio | -18.18 | -4.86 | -22.75 | -2.08 | -2.88 |
| Interest Coverage Ratio | -21.01 | -6.00 | -1216.44 | -2.19 | -3.23 |
| Debt to Market Cap | 0.18 | 0.10 | 8.50 | 3.60 | 1.14 |
| Interest Debt Per Share | 11.25 | 4.37 | 52.65 | 141.04 | 317.79 |
| Net Debt to EBITDA | -0.09 | -0.02 | -1.71 | -0.71 | -1.14 |
| Profitability Margins | |||||
| Gross Profit Margin | -202.29% | -88.15% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -606.25% | -1312.77% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | -497.86% | -1062.16% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -575.29% | -1312.77% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | -633.64% | 728.88% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | -633.64% | 728.88% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -633.64% | 728.88% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 110.14% | -55.52% | 66.97% | 52.40% | 75.46% |
| Return on Assets (ROA) | -71.45% | 35.66% | -37.20% | -21.41% | -25.61% |
| Return on Equity (ROE) | -102.52% | 48.07% | 142.26% | 329.32% | -835.64% |
| Return on Capital Employed (ROCE) | -75.11% | -74.20% | -61.85% | -44.73% | -36.75% |
| Return on Invested Capital (ROIC) | -72.73% | -71.59% | -58.88% | -44.05% | -35.99% |
| Return on Tangible Assets | -71.45% | 35.66% | -37.20% | -21.41% | -25.61% |
| Earnings Yield | -499.69% | 177.54% | -279.64% | -103.87% | -34.04% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.80 | 3.03 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 9.74 | 3.29 | 0.96 | 0.78 | 0.75 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.14 | 0.06 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.11 | 0.05 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 2.49 | 0.31 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 9.29 | 9.52 | -380.89 | -466.84 | -487.71 |
| Days of Sales Outstanding | 46.77 | 120.37 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 37.49 | 110.86 | 380.89 | 466.84 | 487.71 |
| Operating Cycle | 46.77 | 120.37 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -25.83 | -7.86 | -24.02 | -38.54 | -72.40 |
| Free Cash Flow Per Share | -25.93 | -7.87 | -25.65 | -42.97 | -73.75 |
| Dividend Paid and CapEx Coverage Ratio | -251.29 | -527.92 | -14.73 | -8.69 | -55.78 |
| Capital Expenditure Coverage Ratio | -251.29 | -527.92 | -14.73 | -8.69 | -55.78 |
| Operating Cash Flow Coverage Ratio | -2.66 | -3.04 | -0.46 | -0.34 | -0.25 |
| Operating Cash Flow to Sales Ratio | -4.60 | -9.63 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -364.23% | -234.96% | -431.03% | -145.17% | -31.38% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.20 | 0.56 | -0.36 | -0.96 | -2.94 |
| Price-to-Sales (P/S) Ratio | 1.27 | 4.11 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.21 | 0.27 | -0.51 | -3.17 | 24.55 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.27 | -0.43 | -0.23 | -0.69 | -3.19 |
| Price-to-Operating Cash Flow Ratio | -0.28 | -0.43 | -0.25 | -0.77 | -3.25 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -0.00 | 0.01 | 0.01 | -0.00 |
| Enterprise Value Multiple | -0.35 | -0.40 | -1.96 | -1.24 | -3.46 |
| Enterprise Value | 2.27M | 2.82M | 18.02M | 13.05M | 35.96M |
| EV to EBITDA | -0.35 | -0.40 | -1.96 | -1.24 | -3.46 |
| EV to Sales | 1.73 | 4.29 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.37 | -0.44 | -1.80 | -1.61 | -4.75 |
| EV to Operating Cash Flow | -0.38 | -0.45 | -1.92 | -1.80 | -4.84 |
| Tangible Book Value Per Share | 34.70 | 12.37 | -11.70 | -9.34 | 9.57 |
| Shareholders’ Equity Per Share | 34.70 | 12.37 | -11.70 | -9.34 | 9.57 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 5.61 | 0.82 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -35.58 | 5.95 | -16.64 | -30.74 | -80.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.05 | -0.56 | 0.67 | 0.52 | 0.76 |
| Research & Development to Revenue | 1.81 | 8.41 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 1.92 | 3.84 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.23 | 1.04 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.73 | -1.32 | 1.44 | 1.25 | 0.90 |
Currency in USD